Recursion Pharmaceuticals (RXRX) just posted another heavily loss making quarter, with Q3 FY 2025 revenue of US$5.2 million against a net loss of US$162.3 million and basic EPS of a US$0.36 loss. The company has seen quarterly revenue move between US$26.1 million in Q3 FY 2024 and US$4.5 million in Q4 FY 2024, while quarterly EPS has ranged from a US$0.34 loss to a US$0.53 loss over that period. This underscores a business that is still in investment mode rather than profit harvesting. For investors, the focus this quarter is on how much of that heavy spend is translating into progress on the pipeline and whether margins can realistically move closer to break even over time.

See our full analysis for Recursion Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this latest set of results lines up against the prevailing narratives around Recursion, from high growth potential to ongoing dilution and deep losses.

Trailing losses tower over revenue base

• On a trailing 12 month view, Recursion generated US$43.7 million of revenue against a net loss of US$715.5 million, so every dollar of revenue currently sits next to a very large loss figure.
• Bears point to this gap as a core risk, and the recent quarters back them up:
  • Quarterly revenue over the last six periods sat in a US$4.5 million to US$26.1 million range, while quarterly net losses ranged from US$95.8 million to US$202.5 million. This lines up with the cautious view that cash outflows remain heavy without commercial products yet.
  • That same bearish view highlights that analysts are not forecasting profitability over the next three years, and the current loss profile of US$715.5 million on US$43.7 million of trailing revenue illustrates why many see earnings risk as front and center.

Recursion’s latest figures have some investors asking whether the downside case is already priced in or only just getting started. The full bear thesis lays out the risks in more detail here: 🐻 Recursion Pharmaceuticals Bear Case

Fast revenue forecasts meet steep losses

• Revenue is forecast in the data to grow about 52.8% per year, yet the company remains loss making with trailing 12 month basic EPS of a US$1.78 loss and a trailing net loss of US$715.5 million.
• Bulls argue that Recursion’s AI driven drug discovery platform can eventually make those growth rates matter, but the current numbers set a high bar:
  • The bullish narrative talks about potentially higher than industry revenue growth, and the 52.8% figure in the analysis is well above the 10.4% referenced for the broader US market. This supports the idea that top line momentum could be different from a typical biotech.
  • At the same time, losses have expanded at about 36% per year over five years according to the analysis, which challenges the bullish hope that operating leverage is already starting to come through the income statement.

Supporters of the growth story often focus on those higher revenue assumptions and pipeline potential, and you can see how they build that case in the full bull thesis here: 🐂 Recursion Pharmaceuticals Bull Case

Valuation signals pull in opposite directions

• The stock trades on a P/S of 42.1x versus 9.4x for peers and 11.9x for the US biotech group, while a DCF fair value of about US$9.59 sits well above the current share price of US$3.77.
• Consensus style views in the analysis treat this as a tension rather than a clear win for either side:
  • On one hand, the commentary notes that the market price is roughly 63.2% below the DCF fair value, which lines up with arguments that the shares could be pricing in a lot of execution risk already.
  • On the other hand, the very high 42.1x P/S multiple relative to peers and industry suggests the market is still paying a premium for revenue today, which echoes the more cautious comments that investors are being asked to pay up even though the business is not yet profitable.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Recursion Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between heavy losses and ambitious growth hopes, now is a good time to look through the numbers yourself and weigh both sides carefully. To see how the trade off between those concerns and potential upsides compares in the data, take a close look at 2 key rewards and 2 important warning signs.

See What Else Is Out There

Recursion is carrying very large losses relative to its modest revenue base, with earnings still deep in the red and profitability not forecast in the near term.

If that scale of ongoing losses makes you want something steadier, check out our 79 resilient stocks with low risk scores to focus on companies with more resilient profiles and tighter risk controls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.